Molbio Diagnostics Limited

Molbio Diagnostics Limited

1,237.65
INR
-22.75
(-1.80%)
13.10EPS
Molbio Diagnostics Limited
BSE:MOLBIO
(Bombay Stock Exchange)

Recent

price

1,237.65

P/E

ratio

- -

div

yld

- -

ROIC.AI

2023
2024
2025
2026
INR
25.73
65.41
79.6
112.91
Revenue per Share
-0.06
8.14
11.58
13.29
Basic EPS, GAAP
3.96
-0.52
18.55
0.03
Free Cash Flow per Basic Share
- -
- -
- -
- -
Dividend per Share
57.57
65.7
77.28
93.31
Book Value per Share
49.99
59.78
72.76
74.72
Tangible Book Value per Share
125
125
125
125
Basic Weighted Avg Shares
3,224
8,197
9,975
14,150
Sales/Revenue/Turnover
4.21
26.15
22.95
19.75
Operating Margin (%)
317
410
446
636
Depreciation Expense
-7
1,020
1,451
1,666
Net Income, GAAP
136.11
35.56
28.72
28.99
Effective Tax Rate (%)
-0.23
12.44
14.55
11.77
Profit Margin (%)
3,592
4,804
4,882
8,275
Working Capital
78
198
236
2,396
LT Debt
7,373
8,288
9,673
13,088
Total Equity
- -
9.87
14.65
13.58
Return on Invested Capital (%)
- -
13.83
15.33
13.32
Return on Capital (%)
- -
13.2
16.2
15.59
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

INR

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
35.3%
Free Cash Flow
- -
- -
-99.84%
Net Income, GAAP
- -
- -
14.81%
Sales/Revenue/Turnover
- -
- -
41.85%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
8,197
2025
- -
- -
- -
- -
9,975
2026
- -
- -
- -
- -
14,150

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
8.14
2025
- -
- -
- -
- -
11.58
2026
- -
- -
- -
- -
13.29

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Molbio Diagnostics Limited is a biomedical diagnostics company focused on developing and commercializing rapid molecular testing solutions for infectious diseases and other life-science applications. The company delivers a portfolio of products and services designed to enable rapid, accurate, point-of-care and centralized laboratory testing, with an emphasis on simplifying workflows, reducing turnaround times, and enabling scalable deployment across diverse settings. Main products and services: advanced molecular diagnostic assays and kits for pathogen detection; real-time PCR and isothermal amplification platforms; consumables and reagents including primers, probes, and reaction buffers; integrated testing workflows and sample-to-answer solutions; validation, quality control materials, and proficiency testing services; software and data analytics tools for result interpretation, monitoring, and reporting; contract research and development (R&D) services; regulatory and compliance support including validation documentation and regulatory submissions. Latest major company changes: strategic partnerships and collaborations to expand assay menu and validate new targets; recent funding rounds and/or acquisitions to strengthen product pipeline and manufacturing capability; launches of new diagnostic tests and related platforms; organizational reorganizations to streamline operations and scale up production; expansion of geographic footprint through new partnerships, distributors, and regional manufacturing capabilities; updates to branding or corporate structure reflecting growth. Additional context: operates in the in vitro diagnostic (IVD) industry with segments spanning clinical diagnostics, reference laboratories, and point-of-care testing; targets hospitals, clinics, reference labs, and public health organizations; geographic operations extend to multiple regions with manufacturing and distribution networks; founded with headquarters in India; subsidiaries or parent relationships may exist as part of corporate group structures.